Vaccine Adjuvant

CRR7 Ligands Heighten Gene Vaccine Effectiveness

Published in Gene Therapy Weekly, November 15th, 2001

by Sonia Nichols, senior medical writer - U.S. researchers have determined two important chemokines can increase the effectiveness of vaccines containing DNA and other genetic material.

Scientists at the University of Tennessee, Knoxville, have found that secondary lymphoid tissue chemokine (SLC) and Epstein-Barr virus-induced molecule 1 ligand chemokine (ELC) augment the effectiveness of herpes simplex virus DNA vaccines. These chemokines, codelivered via plasmid DNA, might be an important adjuvant for genetic vaccines used to battle other infectious diseases or cancer, researchers propose.

Both SLC and ELC pave the way for effective immune...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry